{"generic":"Somatropin, E-Coli Derived","drugs":["Genotropin","Genotropin Miniquick","Humatrope","Norditropin","Nutropin","Nutropin AQ Pen","Omnitrope","Somatropin, E-Coli Derived","Tev-Tropin"],"mono":{"0":{"id":"559330-s-0","title":"Generic Names","mono":"Somatropin, E-Coli Derived"},"1":{"id":"559330-s-1","title":"Dosing and Indications","sub":[{"id":"559330-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Growth hormone deficiency:<\/b> Genotropin(R), weight-based dosing schedule: initial, not more than 0.04 mg\/kg\/WEEK SUBQ given as a daily divided dose; increase at 4- to 8-week intervals up to a MAX dose of 0.08 mg\/kg\/wk<\/li><li><b>Growth hormone deficiency:<\/b> Genotropin(R), alternative dosing schedule: initial, 0.2 mg\/DAY (range, 0.15 to 0.3 mg\/day) SUBQ; increase by 0.1 to 0.2 mg\/day every 1 to 2 months according to patient response<\/li><li><b>Growth hormone deficiency:<\/b> Humatrope(R), weight-based dosing: initial, not more than 0.006 mg\/kg\/DAY SUBQ; may increase up to MAX dose 0.0125 mg\/kg\/day<\/li><li><b>Growth hormone deficiency:<\/b> Humatrope(R), alternative dosing schedule: initial, 0.2 mg\/DAY (range, 0.15 to 0.3 mg\/day) SUBQ; increase by 0.1 to 0.2 mg\/day every 1 to 2 month according to patient response<\/li><li><b>Growth hormone deficiency:<\/b> Norditropin(R), weight-based dosing: initial, not more than 0.004 mg\/kg\/day SUBQ; may increase dose up to a MAX dose of 0.016 mg\/kg\/day after approximately 6 weeks<\/li><li><b>Growth hormone deficiency:<\/b> Norditropin(R), alternative dosing schedule: initial, 0.2 mg\/day (range, 0.15 to 0.3 mg\/day) SUBQ; increase by 0.1 to 0.2 mg\/day every 1 to 2 months according to patient response<\/li><li><b>Growth hormone deficiency:<\/b> Nutropin(R), Nutropin AQ(R), weight-based dosing: initial, not more than 0.006 mg\/kg\/DAY SUBQ; may increase up to a MAX dose of 0.025 mg\/kg daily (35 years or younger) OR to MAX dose of 0.0125 mg\/kg daily (older than 35 years)<\/li><li><b>Growth hormone deficiency:<\/b> Nutropin(R), Nutropin AQ(R): initial, alternative dosing schedule: initial, 0.2 mg\/DAY (range, 0.15 to 0.3 mg\/day) SUBQ; increase by 0.1 to 0.2 mg\/day every 1 to 2 months according to patient response<\/li><li><b>Growth hormone deficiency:<\/b> Nutropin(R) Depot: 1.5 mg\/kg\/MONTH SUBQ (same day each month) OR 0.75 mg\/kg twice each month SUBQ (same days each month); some patients will require more than 1 injection\/dose<\/li><li><b>Growth hormone deficiency:<\/b> Omnitrope(R): initial, not more than 0.04 mg\/kg\/WEEK SUBQ given as a daily divided dose, preferably in the evening; may increase at 4- to 8-week intervals to a MAX of 0.08 mg\/kg\/week<\/li><li><b>Growth hormone deficiency:<\/b> Omnitrope(R), alternative dosing schedule: initial, 0.2 mg\/DAY (range, 0.15 to 0.3 mg\/day) SUBQ; increase by 0.1 to 0.2 mg\/day every 1 to 2 months according to patient response<\/li><li><b>Growth hormone deficiency:<\/b> guideline (The Endocrine Society): individualize dose, start low and titrate according to clinical response, side effects and insulin-like growth factor-I (IGF-I) levels<\/li><li><b>Growth hormone deficiency:<\/b> guideline (AACE): younger than 30 years, 0.4 to 0.5 mg\/day SUBQ; 30 to 60 years of age, 0.2 to 0.3 mg\/day SUBQ; older than 60 years of age, 0.1 to 0.2 mg\/day SUBQ; patients with diabetes or who are susceptible to glucose intolerance, start with 0.1 to 0.2 mg\/day<\/li><li><b>Growth hormone deficiency:<\/b> guideline (AACE): increase dose in increments of 0.1 to 0.2 mg\/day at 1 to 2 month intervals based on clinical response, serum insulin-like growth factor levels, side effects, and individual considerations such as glucose intolerance<\/li><\/ul>"},{"id":"559330-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>response to growth hormone declines over time; if growth rate is not increased, particularly in the first year, evaluate compliance and other causes of growth failure; dosage and administration should be individualized for each patient; discontinue if epiphyseal fusion has occurred<\/li><li><b>Decreased body growth - Prader-Willi syndrome:<\/b> Genotropin(R): 0.24 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Decreased body growth - Prader-Willi syndrome:<\/b> Omnitrope: 0.24 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk, preferably in the evening<\/li><li><b>Growth hormone deficiency:<\/b> Accretropin(R): 0.18 to 0.3 mg\/kg\/WEEK SUBQ, divided into equal daily doses given 6 or 7 days\/week<\/li><li><b>Growth hormone deficiency:<\/b> Genotropin(R): 0.16 to 0.24 mg\/kg\/WEEK SUBQ, divided into equal daily doses given 6 or 7 days\/week<\/li><li><b>Growth hormone deficiency:<\/b> Humatrope(R): 0.18 to 0.3 mg\/kg\/WEEK SUBQ, divided into equal daily doses<\/li><li><b>Growth hormone deficiency:<\/b> Norditropin(R): 0.024 to 0.034 mg\/kg\/DAY SUBQ, administered 6 to 7 times\/wk; discontinue once epiphyses are fused<\/li><li><b>Growth hormone deficiency:<\/b> Nutropin(R), Nutropin AQ(R): 0.3 mg\/kg\/WEEK SUBQ, divided into equal doses and given daily; a dose of up to 0.7 mg\/kg\/WEEK SUBQ (divided into daily doses) may be used for pubertal patients<\/li><li><b>Growth hormone deficiency:<\/b> Nutropin(R) Depot: 1.5 mg\/kg\/MONTH SUBQ (same day each month) OR 0.75 mg\/kg twice each month SUBQ (same days each month); some patients will require more than 1 injection\/dose<\/li><li><b>Growth hormone deficiency:<\/b> Omnitrope(R): 0.16 to 0.24 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk, preferably in the evening<\/li><li><b>Growth hormone deficiency:<\/b> Zomacton (TM): 0.1 mg\/kg SUBQ 3 times per week (up to 0.3 mg\/kg\/week)<\/li><li><b>Noonan's syndrome - Short stature disorder:<\/b> Norditropin(R): up to 0.066 mg\/kg\/day SUBQ; discontinue once epiphyses are fused<\/li><li><b>Renal function impairment with growth failure:<\/b> Nutropin(R), Nutropin AQ(R): up to 0.35 mg\/kg\/WEEK SUBQ, divided into equal daily doses; may continue up to time of renal transplantation<\/li><li><b>Short stature disorder, Idiopathic:<\/b> Omnitrope(R): up to 0.47 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk, preferably in the evening<\/li><li><b>Short stature disorder, Idiopathic:<\/b> Genotropin(R): up to 0.47 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Short stature disorder, Idiopathic:<\/b> Humatrope(R): up to 0.37 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Short stature disorder, Idiopathic:<\/b> Nutropin(R), Nutropin AQ(R): up to 0.3 mg\/kg\/WEEK SUBQ, divided into equal daily doses<\/li><li><b>Short stature disorder, Short-stature homeobox-containing gene (SHOX) deficiency:<\/b> Humatrope(R): weekly dosage of 0.35 mg\/kg SUBQ divided into equal daily doses and given 6 to 7 times per week<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Accretropin(R): 0.36 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Humatrope(R): up to 0.375 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Genotropin(R): 0.33 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Norditropin(R): up to 0.067 mg\/kg\/day SUBQ, discontinue when the epiphyses are fused<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Nutropin(R), or Nutropin AQ(R): up to 0.375 mg\/kg\/WEEK SUBQ, divided into equal doses given 3 to 7 days\/wk<\/li><li><b>Short stature disorder - Turner syndrome:<\/b> Omnitrope(R): 0.33 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk, preferably in the evening<\/li><li><b>Small for gestational age baby, with no catch-up growth by age 2 to 4 years:<\/b> Genotropin(R): up to 0.48 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk<\/li><li><b>Small for gestational age baby, with no catch-up growth by age 2 to 4 years:<\/b> Omnitrope(R): up to 0.48 mg\/kg\/WEEK SUBQ, divided into equal doses given 6 or 7 days\/wk, preferably in the evening<\/li><li><b>Small for gestational age baby, with no catch-up growth by age 2 to 4 years:<\/b> Humatrope(R), height standard deviation score between -2 and -3, age generally less than 4 years: initial, 0.033 mg\/kg\/DAY SUBQ<\/li><li><b>Small for gestational age baby, with no catch-up growth by age 2 to 4 years:<\/b> Humatrope(R), height standard deviation score less than -3 and\/or older\/pubertal age: initial, 0.067 mg\/kg\/DAY SUBQ; reduce dose toward 0.033 mg\/kg\/DAY if substantial growth catch-up occurs in first few years of treatment<\/li><li><b>Small for gestational age baby, with no catch-up growth by age 2 to 4 years:<\/b> Norditropin(R), up to 0.067 mg\/kg\/day SUBQ<\/li><\/ul>"},{"id":"559330-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>elderly:<\/b> lower starting dose  and use smaller dose increments<\/li><li><b>female gender:<\/b> oral estrogen replacement may require higher doses<\/li><li><b>obese:<\/b> may experience more adverse events when weight-based regimens used<\/li><\/ul>"},{"id":"559330-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Decreased body growth - Prader-Willi syndrome<\/li><li>Growth hormone deficiency<\/li><li>Noonan's syndrome - Short stature disorder<\/li><li>Renal function impairment with growth failure<\/li><li>Short stature disorder, Idiopathic<\/li><li>Short stature disorder, Short-stature homeobox-containing gene (SHOX) deficiency<\/li><li>Short stature disorder - Turner syndrome<\/li><li>Small for gestational age baby, with no catch-up growth by age 2 to 4 years<\/li><\/ul>"}]},"3":{"id":"559330-s-3","title":"Contraindications\/Warnings","sub":[{"id":"559330-s-3-9","title":"Contraindications","mono":"<ul><li>Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma; increased mortality has been reported<\/li><li>Acute respiratory failure; increased mortality has been reported<\/li><li>Active malignancy<\/li><li>Active proliferative or severe non-proliferative diabetic retinopathy<\/li><li>Closed epiphyses in pediatric patients<\/li><li>Hypersensitivity to somatropin, Escherichia coli, or any of its excipients or diluents<\/li><li>Hypersensitivity to benzyl alcohol-containing diluent<\/li><li>Hypersensitivity to metacresol-containing diluent<\/li><li>Prader-Willi syndrome, in patients who are severely obese, have severe respiratory impairment, or have a history of upper airway obstruction or sleep apnea<\/li><li>Progression or recurrence of underlying intracranial tumor<\/li><\/ul>"},{"id":"559330-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Fluid retention may occur in adults<\/li><li>-- Increased risk of cardiovascular diseases (such as hypertension, aortic aneurysm or dissection, stroke) in patients with Turner Syndrome<\/li><li>Dermatologic Effects:<\/li><li>-- Monitor for growth or malignant changes in preexisting nevi<\/li><li>-- Tissue atrophy may occur with long-term focal subQ administration; rotate injection site<\/li><li>Endocrine Metabolic Effects:<\/li><li>-- New or worsening hyperglycemia, glucose intolerance, or diabetes mellitus may occur; monitoring recommended, especially in patients with risk factors for diabetes<\/li><li>-- Hypopituitarism; monitoring of other hormonal deficiencies recommended; monitoring of other hormonal replacement therapies recommended<\/li><li>-- Undiagnosed or untreated hypothyroidism may prevent optimal response to somatropin and growth response in children; monitoring recommended<\/li><li>Gastrointestinal Effects:<\/li><li>-- Pancreatitis has been reported, with greater risk in children<\/li><li>Immunologic:<\/li><li>-- Systemic or local allergic reactions may occur<\/li><li>-- Hypersensitivity to glycerin or metacresol<\/li><li>-- Increased risk of second neoplasm (eg, intracranial tumors, particularly meningiomas) in childhood cancer survivors treated with radiation to the head\/brain who subsequently developed growth hormone deficiency (GHD) and were treated with somatropin; routine monitoring for progression or recurrence of tumor recommended in patients with preexisting tumors or GHD secondary to an intracranial neoplasm<\/li><li>Some rare genetic causes of short stature in children can increase risk of developing malignancies, consider risk versus benefit of somatropin therapy; monitoring for development of neoplasms recommended<\/li><li>Musculoskeletal Effects:<\/li><li>-- Increased risk of slipped capital femoral epiphysis in pediatric patients<\/li><li>-- Scoliosis may progress with rapid growth in pediatric patients; monitoring recommended<\/li><li>-- Epiphyseal maturation may occur more rapidly in pubertal patients and those receiving concurrent thyroid replacement therapy; monitoring recommended<\/li><li>Neurologic:<\/li><li>-- Intracranial hypertension with papilledema has been reported, increased risk in Prader-Willi syndrome, Turner syndrome, and chronic renal insufficiency patients  and after treatment with IGF-1; monitoring recommended and discontinuation of therapy may be necessary; may reinitiate at lower dose once signs and symptoms resolved<\/li><li>Ophthalmic Effects:<\/li><li>-- Papilledema; initial screening and monitoring recommended; discontinue if condition occurs<\/li><li>Otic Effects:<\/li><li>-- Increased risk of ear and hearing disorders in patient with Turner Syndrome; monitoring recommended<\/li><li>Renal Effects:<\/li><li>-- Pediatric patients with chronic kidney disease at increased risk for new or worsening renal osteodystrophy; baseline evaluation and monitoring recommended<\/li><li>Respiratory Effects:<\/li><li>-- Acute respiratory failure in patients on replacement doses of somatropin may increase mortality risk<\/li><li>Other:<\/li><li>-- Life-threatening and fatal gasping syndrome has occurred in neonatal and pediatric patients with benzyl alcohol exposure (a preservative in Bacteriostatic Water for Injection, USP diluent); monitor total daily metabolic load from all sources<\/li><li>-- Increased mortality has been reported in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma in patients on replacement doses of somatropin<\/li><li>-- Increased mortality risk in pediatric patients with Prader-Willi syndrome and severe obesity, history of upper airway obstruction or sleep apnea, or respiratory infection, especially males; baseline evaluation and ongoing monitoring recommended; treatment interruption may be required with signs of upper airway obstruction (eg, snoring) or new-onset sleep apnea<\/li><\/ul>"},{"id":"559330-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Somatropin: C (FDA)<\/li><li>Somatropin: B2 (AUS)<\/li><\/ul>"},{"id":"559330-s-3-12","title":"Breast Feeding","mono":"Somatropin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"559330-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema of lower extremity (15%), Peripheral edema (up to 42%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction, Lipoatrophy<\/li><li><b>Hematologic:<\/b>Eosinophil count raised (11% to 12%), Hematoma (9%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (up to 27%), Myalgia (adult, up to 15%; pediatric, up to 24.3%)<\/li><li><b>Neurologic:<\/b>Headache (adult, up to 10.9%; pediatric, 7%), Paresthesia (up to 17.3%)<\/li><li><b>Respiratory:<\/b>Rhinitis (up to 13.5%)<\/li><li><b>Other:<\/b>Influenza-like symptoms (up to 22.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Disorder of cardiovascular system, In patients with Turner syndrome, Edema (adult, up to 41%; pediatric, 2.5%)<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus (0.4%), Hypothyroidism (16%), Impaired glucose tolerance (6%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis (rare)<\/li><li><b>Musculoskeletal:<\/b>Scoliosis deformity of spine, Progression (18.9%), Slipped upper femoral epiphysis<\/li><li><b>Neurologic:<\/b>Intracranial tumor, Pseudotumor cerebri<\/li><li><b>Otic:<\/b>Otitis media, In pediatric patients (up to 86.4%)<\/li><\/ul>"},"6":{"id":"559330-s-6","title":"Drug Name Info","sub":{"0":{"id":"559330-s-6-17","title":"US Trade Names","mono":"<ul><li>Genotropin<\/li><li>Humatrope<\/li><li>Norditropin<\/li><li>Nutropin<\/li><li>Tev-Tropin<\/li><li>Omnitrope<\/li><li>Genotropin Miniquick<\/li><li>Nutropin AQ Pen<\/li><\/ul>"},"2":{"id":"559330-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Pituitary Hormone, Anterior<\/li><\/ul>"},"3":{"id":"559330-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"559330-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"559330-s-7","title":"Mechanism Of Action","mono":"Somatropin is a recombinant polypeptide hormone with primary structure identical to that of human growth hormone. It can affect linear growth rate and increase concentrations of Insulin-like Growth Factor-I\/Somatomedin-C (IGF-I). In addition, it also act on tissue growth, protein, carbohydrate, lipid, and mineral metabolism.<br\/>"},"8":{"id":"559330-s-8","title":"Pharmacokinetics","sub":[{"id":"559330-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability: (IM), 63%<\/li><li>Bioavailability: (Subcutaneous, Humatrope(R)), 75%<\/li><li>Bioavailability: (Subcutaneous; Accretropin(TM)), 70%<\/li><\/ul>"},{"id":"559330-s-8-24","title":"Distribution","mono":"<ul><li>Vd: (IM), 1.55 L\/kg +\/- 0.91 L\/kg<\/li><li>Vd: (IV), 0.0703 L\/kg +\/- 0.0173 L\/kg<\/li><li>Vd: (Subcutaneous), 0.957 L\/kg +\/- 0.301 L\/kg<\/li><li>Vd: (Subcutaneous) healthy adults, 1.4 L\/kg<\/li><\/ul>"},{"id":"559330-s-8-25","title":"Metabolism","mono":"Hepatic and Renal; extensive, classical protein catabolism <br\/>"},{"id":"559330-s-8-26","title":"Excretion","mono":"Renal <br\/>"},{"id":"559330-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(IM), 4.93 hr +\/- 2.66 hr<\/li><li>(IV), 0.363 hr +\/- 0.053 hr<\/li><li>(Subcutaneous; Humatrope(R)), 3.81 hr +\/- 1.4 hr<\/li><li>(Subcutaneous; Accretropin(TM)), 3.63 +\/- 1.33 hr<\/li><li>(Subcutaneous), healthy adults, 2.4 hr<\/li><\/ul>"}]},"9":{"id":"559330-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>Humatrope(R), Genotropin(R), Norditropin(R), Nutropin(R), Omnitrope(R), Accretropin(R), only give SUBQ<\/li><li>Genotropin(R), Omnitrope(R), and Accretropin(R) must not be used intravenously.<\/li><li>Do not shake during reconstitution; swirl vial gently.<\/li><li>Do not inject if solution is cloudy or contains particles.<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Genotropin(R) and Omnitrope(R): Administer in the thigh, buttocks, or abdomen; rotate the site daily to help prevent lipoatrophy; Omnitrope(R) should be administered preferably in the evening.<\/li><li>Prefilled Omnitrope(R) cartridges: 5 mg\/1.5 mL and 10 mg\/1.5 mL must be used with their corresponding Pen 5 and Pen 10 injection delivery systems.<\/li><li>Norditropin(R): Must be administered using the NordiPen delivery systems; do not inject if cloudy or contains particulates.<\/li><li>Norditropin(R): Always rotate the injection site to help prevent lipoatrophy<\/li><li>Humatrope(R): Reconstitute vials with provided diluent or bacteriostatic water for injection or sterile water for injection if sensitivity occurs to diluent; do not reconstitute with bacteriostatic water for injection for use in newborns.<\/li><li>Humatrope(R) cartridge: Reconstitute with diluent provided; do not reconstitute with diluent for vials; only use injection device provided with cartridge.<\/li><li>Humatrope(R) cartridge: Reconstitute with diluent provided; do not use diluent for vials; only use injection device provided with cartridge,.<\/li><li>Nutropin(R): Reconstitute using bacteriostatic water for injection.<\/li><li>Nutropin(R), newborns: Reconstitute using sterile water for injection; do NOT use bacteriostatic water for injection (toxicity with benzyl alcohol).<\/li><li>Zomacton(TM) 5-mg vial: Reconstitute with 1 to 5 mL bacteriostatic water for injection; may refrigerate reconstituted solution up to 14 days.<\/li><li>Zomacton(TM) 5-mg vial: For use in newborns, reconstitute with sterile NS.<\/li><li>Zomacton(TM) 10-mg vial: Reconstitute with provided 1-mL syringe of bacteriostatic water for injection preserved with 0.33% metacresol; may refrigerate reconstituted solution up to 28 days.<\/li><li>Zomacton(TM): Administer 5-mg or 10 mg vial with standard sterile disposable syringe or ZOMA-Jet(TM) needle-free injection device.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"559330-s-10","title":"Monitoring","mono":"<ul><li>Serum insulin-like growth factor (IGF-I) levels; in adults with growth hormone deficiency, at 1- to 2-month intervals following initiation of therapy; once the maintenance dose has been achieved, and at 6- to 12-month intervals for dose-adjustment guidance<\/li><li>Glucose levels; in all patients, particularly in those with risk factors for diabetes mellitus; closer monitoring is recommended for patients with preexisting type 1 or type 2 diabetes<\/li><li>HbA1c levels; at 6 to 12-month intervals in adults with growth hormone deficiency, after achieving maintenance dose<\/li><li>Thyroid function tests; periodically<\/li><li>Fasting lipid panel; annually in adults with growth hormone deficiency, once maintenance dose has been achieved<\/li><li>Upper airway obstructions or sleep apnea, in patients with Prader-Willi syndrome; before treatment initiation.<\/li><li>Respiratory infection, in patients with Prader-Willi syndrome.<\/li><li>Funduscopic examinations; before initiating treatment and periodically thereafter<\/li><li>Progression or recurrence of neoplasm; routinely in patients with preexisting tumors and those with an increased risk of developing malignancy<\/li><li>Increased growth or potential malignant changes of preexisting nevi<\/li><li>Progression of scoliosis<\/li><li>Hormone replacement therapies; in patients with hypopituitarism during somatropin therapy<\/li><li>Bone age, especially in patients who are pubertal and in those receiving concomitant thyroid hormone replacement therapy; periodically<\/li><li>Bone dual-energy X-ray absorptiometry (DEXA) scan, prior to initiation of therapy and if abnormal repeat evaluations at 2- to 3-year intervals during therapy<\/li><li>Otitis media, ear disorders, or cardiovascular disorders; in patients with Turner Syndrome<\/li><li>Progression of renal osteodystrophy; periodically during therapy<\/li><\/ul>"},"11":{"id":"559330-s-11","title":"How Supplied","mono":"<ul><li><b>Genotropin Miniquick<\/b><br\/>Subcutaneous Powder for Solution: 0.2 MG, 0.4 MG, 0.6 MG, 0.8 MG, 1 MG, 1.2 MG, 1.4 MG, 1.6 MG, 1.8 MG, 2 MG<br\/><\/li><li><b>Genotropin<\/b><br\/>Subcutaneous Powder for Solution: 5.8 MG, 13.8 MG<br\/><\/li><li><b>Humatrope<\/b><br\/><ul><li>Injection Powder for Solution: 6 MG, 12 MG, 24 MG<\/li><li>Subcutaneous Powder for Solution: 5 MG<\/li><\/ul><\/li><li><b>Norditropin Flexpro<\/b><br\/>Subcutaneous Solution: 5 MG\/1.5 ML, 10 MG\/1.5 ML, 30 MG\/3 ML, 15 MG\/1.5 ML<br\/><\/li><li><b>Norditropin Nordiflex<\/b><br\/>Subcutaneous Solution: 30 MG\/3 ML<br\/><\/li><li><b>Nutropin AQ NuSpin 10<\/b><br\/>Subcutaneous Solution: 5 MG\/ML<br\/><\/li><li><b>Nutropin AQ NuSpin 20<\/b><br\/>Subcutaneous Solution: 10 MG\/ML<br\/><\/li><li><b>Nutropin AQ NuSpin 5<\/b><br\/>Subcutaneous Solution: 5 MG\/2 ML<br\/><\/li><li><b>Nutropin AQ Pen Cartridge<\/b><br\/>Subcutaneous Solution: 5 MG\/ML<br\/><\/li><li><b>Nutropin AQ Pen<\/b><br\/>Subcutaneous Solution: 10 MG\/ML<br\/><\/li><li><b>Nutropin<\/b><br\/>Subcutaneous Powder for Solution: 10 MG<br\/><\/li><li><b>Omnitrope<\/b><br\/><ul><li>Subcutaneous Powder for Solution: 5.8 MG<\/li><li>Subcutaneous Solution: 5 MG\/1.5 ML, 10 MG\/1.5 ML<\/li><\/ul><\/li><li><b>Zomacton<\/b><br\/>Subcutaneous Powder for Solution: 5 MG, 10 MG<br\/><\/li><\/ul>"},"12":{"id":"559330-s-12","title":"Toxicology","sub":[{"id":"559330-s-12-31","title":"Clinical Effects","mono":"<b>SOMATROPIN<\/b><br\/>BACKGROUND: A biosynthetic polypeptide hormone with an amino acid sequence identical to human growth hormone. OVERDOSE: Data are limited. Hyperglycemia may occur with an acute exposure. Pituitary atrophy reported after long-term misuse.  Gigantism and\/or acromegaly may occur after long-term overdosage. ADVERSE EFFECTS: Peripheral edema, pancreatitis, hypo- and hyperglycemia, hypothyroidism, intracranial hypertension, tachycardia, hypertension, HA, agitation, fatigue, seizures, N\/V, hematuria, muscle and joint pain, and increased alkaline phosphatase have been reported.  OTHER: Somatropin products may contain benzyl alcohol (an antimicrobial preservative), which has been associated with toxicity in newborns. <br\/>"},{"id":"559330-s-12-32","title":"Treatment","mono":"<b>SOMATROPIN<\/b><br\/><ul><li>Decontamination: Not indicated. Subcutaneous administration.<\/li><li>Support: No antidote is available.  Overdose treatment is symptomatic and supportive<\/li><li>Monitoring of patient: Obtain baseline blood glucose level; repeat as indicated. Monitor thyroid function following an overdose.<\/li><\/ul>"},{"id":"559330-s-12-33","title":"Range of Toxicity","mono":"<b>SOMATROPIN<\/b><br\/>A minimum toxic dose has not been established. <br\/>"}]},"13":{"id":"559330-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause hypothyroidism, edema, arthralgia, myalgia, carpal tunnel syndrome, paraesthesias, and injection site reactions.<\/li><li>This drug may cause intracranial hypertension and fluid retention.<\/li><li>Drug may also cause progression of scoliosis or slipped capital femoral epiphysis in rapidly growing children.<\/li><li>This drug may cause hypo- or hyperglycemia and reduced insulin sensitivity. Advise diabetic patients to monitor for and report changes in glycemic control, as insulin dosage may need to be adjusted.<\/li><li>Patient should also monitor for and report increased growth or unusual changes to moles or other skin growths.<\/li><li>Advise patient to report signs\/symptoms of pancreatitis, upper airway obstruction, and sleep apnea.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}